Biotechnology - Publications - Faculty & Research - Harvard Business School

Filter Results: (622)

Filter Results: (622)

Show Results For

← Page 25 of 622 Results →

January 2009 (Revised July 2009)
Case

Targanta Therapeutics: Hitting a Moving Target

By: Arthur A. Daemmrich

This case explores regulatory, product testing, and business strategy at Targanta Therapeutics, a biotech company preparing its first new drug application to the FDA. In October 2007, Mark Leuchtenberger, president and CEO of Targanta—which has just held a successful... View Details

Keywords: Decision Choices and Conditions; Entrepreneurship; Governing Rules, Regulations, and Reforms; Health Testing and Trials; Product Development; Business and Government Relations; Business Strategy; Biotechnology Industry; Biotechnology Industry

September 2008
Teaching Note

Chi Mei Optoelectronics (TN)

By: Willy C. Shih

Teaching Note for [608-123]. View Details

Keywords: Diversification; Information Technology; Market Entry and Exit; Standards; Industry Clusters; Supply Chain; Production; Experience and Expertise; Biotechnology Industry; Biotechnology Industry; Taiwan; Asia; Korean Peninsula; China

September 2007 (Revised May 2009)
Case

Syndexa and Technology Transfer at Harvard University

By: Richard G. Hamermesh and David Kiron

Gokhan Hotamisligil is a star researcher at Harvard School of Public Health who has made groundbreaking discoveries linking fat cells, inflammation, and diabetes. He now wants to form a company to commercialize these discoveries. At the same time, Isaac Kohlberg, the... View Details

Keywords: Business Startups; Higher Education; Entrepreneurship; Innovation and Invention; Intellectual Property; Rights; Agreements and Arrangements; Science-Based Business; Commercialization; Biotechnology Industry; Biotechnology Industry

November 2006 (Revised March 2008)
Case

The Harvard Stem Cell Institute

By: William A. Sahlman

Describes a set of issues confronting the leaders of the Harvard Stem Cell Institute, an innovative cross-university effort to accelerate scientific discovery and translation in the domain of stem cells. Covers a wide range of topics, including understanding how... View Details

Keywords: Talent and Talent Management; Higher Education; Entrepreneurship; Collaborative Innovation and Invention; Intellectual Property; Research and Development; Genetics; Biotechnology Industry; Biotechnology Industry; Massachusetts

November 2005 (Revised November 2005)
Case

Massachusetts General Hospital and the Enbrel Royalty

By: David S. Scharfstein and Darren R. Smart

Massachusetts General Hospital is considering selling its royalty interest in Enbrel, Amgen's blockbuster drug for the treatment of rheumatoid arthritis. In assessing whether to sell, and at what price, the hospital must determine its value to a potential buyer as well... View Details

Keywords: Valuation; Price; Investment Return; Capital; Value; Revenue; Health Care and Treatment; Biotechnology Industry; Biotechnology Industry; Massachusetts

March 2005 (Revised August 2005)
Case

Procurement at Betapharm Corp. (A)

Presents a move by Betapharm to centralize procurement and e-sourcing and the many control and incentive issues that arose subsequently. View Details

Keywords: Motivation and Incentives; Governance Controls; Supply Chain Management; Biotechnology Industry; Biotechnology Industry

June 2003 (Revised March 2008)
Case

Schering-Plough and Genome Therapeutics: Discovering an Asthma Gene

By: Regina E. Herzlinger and Marc Aquino

Personalized medicine requires the identification of mutated genes. Schering-Plough's search for the one related to asthma requires finding families with the disease. Examines the industry that helps conduct such research, including contract research organizations. View Details

Keywords: Health Disorders; Research and Development; Genetics; Biotechnology Industry; Biotechnology Industry

November 1998 (Revised October 1999)
Case

E.I. du Pont de Nemours and Company (A)

Du Pont's chief executive must decide what steps to take as his company expands from commodity and specialized chemicals into biotechnology. View Details

Keywords: Technology; Leading Change; Expansion; Biotechnology Industry; Biotechnology Industry

Find at Harvard

September 1997 (Revised October 1997)
Case

Bayer AG (A)

By: John A. Quelch

Bayer's senior executives convene in Germany to consider submitting a $1 billion bid that would recover the Bayer brand name and trademark cross in North America, both of which were confiscated by the U.S. government after World War I. The group also sets out to assess... View Details

Keywords: Management Teams; Brands and Branding; War; Communication; Trademarks; Acquisition; Government and Politics; Biotechnology Industry; Biotechnology Industry; Germany; North America; United States

Find at Harvard

15 Dec 2020
Blog Post

MBA Voices Blog: A Year in Review

decision maker. Read More 4 Things to Know About the MS/MBA Biotech “I was initially attracted to Harvard’s MS/MBA Biotechnology: Life Sciences program because of the emphasis on ethical decision making, and ultimately chose the program with the goal of becoming an... View Details

Profile

Terrance McGuire

and entrepreneur, during which time they have collaborated on a long list of successful biotechnology startups. “Bob Langer is passionate about improving peoples' lives,” McGuire said. “He was one of the early... View Details

22 Nov 2016
First Look

November 22, 2016

commercial implications—the technology would be immensely important to biotechnology firms looking to develop gene therapy products and was, therefore, sure to generate strong revenues for whichever entity owned the IP—but would also... View Details

Keywords: Sean Silverthorne

Aug 2011 - 2011
Conference Presentation

Institutional Heterogeneity, Innovation, and Entrepreneurship in the U.S. Biodiesel Fuel Sector

By: Shon R. Hiatt

Keywords: Innovation and Invention; Entrepreneurship; Business Ventures; Biotechnology Industry; Biotechnology Industry; Biotechnology Industry

2011
Other Unpublished Work

From Farms to Fuel Tanks: Collective Actors and New-Venture Innovation in the U.S. Biodiesel Fuel Sector

By: Shon R. Hiatt

Little is known about the influence of collective actors on innovative technological recombinations by new ventures. Using data from U.S. biodiesel producers, I examine how the efforts of multiple collective actors (farm associations) to promote varying types of... View Details

Keywords: Alliances; Agribusiness; Energy Sources; Innovation and Invention; Biotechnology Industry; Biotechnology Industry; Biotechnology Industry; United States

Research Summary

Overview

By: Kyle R. Myers

Professor Myers studies the economics of what determines the rate and direction of innovation. He has examined the reallocation of scientists through the use of targeted research grants at the National Institutes of Health, and is working to further understand how... View Details

November 2023 (Revised April 2024)
Case

BiomX: Bringing Phage Back to the Stage

By: Paul A. Gompers, Elie Ofek, Orna Dan and Emilie Billaud

In the spring of 2023, and following the favorable results of a trial involving its phage cocktail for treating lung infections among cystic fibrosis (CF) patients, the leadership of BiomX had several critical issues to wrestle with. First, given its precarious... View Details

Keywords: Working Capital; Financing and Loans; Health Testing and Trials; Product Development; Research and Development; Science-Based Business; Commercialization; Biotechnology Industry; Biotechnology Industry

September 2023 (Revised April 2024)
Case

Atomwise: Strategic Opportunities in AI for Pharma

By: Satish Tadikonda

Abraham Heifets and his co-founder, Izhar Wallach, had founded Atomwise to develop i) an AI engine to transform drug discovery by creating better medicines faster, and ii) a machine learning-based discovery engine that combined the power of convolutional neural... View Details

Keywords: Business Model; Business Startups; AI and Machine Learning; Science-Based Business; Technological Innovation; Biotechnology Industry; Biotechnology Industry

January 2014
Supplement

Amgen Inc.: Pursuing Innovation and Imitation? (B)

By: Ian Mackenzie

The (B) case reveals that Sharer decided that Amgen should enter the emerging biosimilars business. However, he took the better part of a year to syndicate the decision across the senior team while in parallel investing in some time-critical process development. The... View Details

Keywords: Corporate Strategy; Biotechnology Industry; Biotechnology Industry; United States

June 2012
Case

GlaxoSmithKline in Brazil: Public-Private Vaccine Partnerships

By: Arthur A. Daemmrich and Ian McKown Cornell

Three years into a major public-private partnership between GlaxoSmithKline and Fiocuz, Brazil's principal health institute, the company assesses technology transfer and joint research under the agreement. GSK was selling its Synflorix vaccine (against pediatric... View Details

Keywords: Public-Private Partnerships; Business and Government Relations; Foreign Direct Investment; Health Care and Treatment; Globalized Firms and Management; Biotechnology Industry; Biotechnology Industry; Brazil

April 2011
Supplement

Roche's Acquisition of Genentech (CW)

By: Bo Becker

Spreadsheet for case 210040. View Details

Keywords: Biotechnology Industry; Biotechnology Industry

←
25
26
…
31
32
→